Table. Characteristics and exposures for hospitalized contact patients with and without transmission of ESBL-producing Escherichia coli from index patients, Basel, Switzerland*.
| Patient characteristics and exposures | Contact patients with transmission of ESBL-producing E. coli, n = 11† | Contact patients without transmission of ESBL-producing E. coli, n = 220† | p value |
|---|---|---|---|
| Contact patient characteristics | |||
| Age, y, median (IQR) | 81 (77–82) | 75 (64–82) | 0.153 |
| Charlson Comorbidity Index, median (IQR) | 2 (1–4) | 2 (1–3) | 0.399 |
| Contact time, d, median (IQR) | 13 (10–15) | 8 (5–12) | 0.006 |
| Intensive care unit stay | 0 | 54 (24.8) | 0.122 |
| Received any antimicrobial drug | 4 (36.4) | 93 (42.3) | 0.765 |
| Received systemic antimicrobial drugs with activity against ESBL E. coli |
1 (9.1) |
19 (8.6) |
1.000 |
| Index patient characteristics | |||
| Age of index patient, y, median (IQR) | 79 (64–87) | 73 (62–80) | 0.175 |
| Charlson Comorbidity Index, median (IQR) | 2 (1–3) | 2 (1–3) | 0.572 |
| Infected with ESBL-producing E. coli | 6 (54.6) | 84 (38.2) | 0.346 |
| ESBL-producing E. coli infection | |||
| Bloodstream | 0 | 3 (1.4)‡ | 1.000 |
| Urinary tract | 5 (45.5) | 68 (30.9) | 0.330 |
| Respiratory tract | 1 (9.1) | 10 (4.6) | 0.422 |
| Surgical site | 0 | 6 (2.7) | 1.000 |
| Colonized with ESBL E. coli | 5 (45.4) | 136 (61.8) | 0.346 |
| Received systemic antimicrobial drugs with activity against ESBL E. coli | 6 (54.6) | 84 (38.2) | 0.346 |
*Bold indicates significance. Contact patient exposures occurred through the sharing of a room for at least 24 hours with an ESBL-producing E. coli–infected or colonized index patient in an acute-care hospital or a geriatric/rehabilitation center. ESBL, extended-spectrum β-lactamase; IQR, interquartile range. †Values are no. (%) patients except as indicated. ‡All patients with bloodstream infections had urinary tract infections.